All In Biotech

Drug Trial Radar · NCT04380519

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)

Last checked: Nov 20, 2026Latest source record: Jan 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

372

Actual

Start

Apr 23, 2020

Primary completion

Jul 10, 2020

Study completion Jul 24, 2020

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
Data Management 365; K-Research, LLC
First posted
May 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study.

Conditions

  • COVID-19

Interventions

  • RPH-104 80 mgDrug

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

  • Olokizumab 64 mgDrug

    solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)

  • PlaceboDrug

    Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Responders in Each Treatment GroupTime frame: Day 15

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Private healthcare institution "Clinical Hospital" Russian Railways-Medicine named after N. A. Semashko"

    Moscow, Russia

  • State Budget Healthcare Institution "City Clinical Hospital № 15 named after O.M. Filatov" of Moscow City Healthcare Department

    Moscow, Russia

  • Federal State Budgetary Institution "Federal Center for Cerebrovascular Pathology and Stroke" of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University)

    Moscow, Russia

  • Federal State Autonomous Education Institution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of the Russian Federation (Sechenov University)

    Moscow, Russia

  • Federal State Budgetary Institution "Central Clinical Hospital with Polyclinic" of Administrative Directorate of the President of the Russian Federation

    Moscow, Russia

  • Federal State Budget Institution "National Medicine Research Center on Cardiology" By Ministry of Healthcare of Russian Federation

    Moscow, Russia

  • State Budget Institution of Healthcare "City Clinical Hospital #52", Moscow City Healthcare Department

    Moscow, Russia

  • State budgetary healthcare institution City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the city of Moscow City Clinical Hospital No. 50

    Moscow, Russia

  • Moscow State Budget Institution of Healthcare "Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"

    Moscow, Russia

  • АО "State Company "Medsi" based on Clinical Hospital №1"

    Moscow, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Volga Research Medical University" of the Ministry of Health of the Russian Federation

    Nizhny Novgorod, Russia

  • Federal Budgetary State Healthcare Institution "National Medical Research Center named after B.A. Almazov"

    Saint Petersburg, Russia

  • Saint-Petersburg State Budget Institution of Healthcare "City Hospital №40"

    Saint Petersburg, Russia

  • Budgetary Health Institution Voronezh Regional Clinical Hospital №1

    Voronezh, Russia

  • State Budget Healthcare Institution of Yaroslavl Region "Yaroslavl Region Clinical Hospital of War Veterans"

    Yaroslavl, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.